R
Ray W. Fuller
Researcher at Eli Lilly and Company
Publications - 353
Citations - 11517
Ray W. Fuller is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Serotonin & Dopamine. The author has an hindex of 56, co-authored 353 publications receiving 11355 citations. Previous affiliations of Ray W. Fuller include Indiana University.
Papers
More filters
Journal ArticleDOI
Vasopressin/Serotonin Interactions in the Anterior Hypothalamus Control Aggressive Behavior in Golden Hamsters
Craig F. Ferris,Richard H. Melloni,Gary A. Koppel,Kenneth W. Perry,Ray W. Fuller,Yvon Delville +5 more
TL;DR: The present studies examine the neuroanatomical and neurochemical interaction between AVP and 5-HT at the level of the anterior hypothalamus (AH) in the control of offensive aggression in Syrian golden hamsters to suggest that5-HT inhibits fighting, in part, by antagonizing the aggression-promoting action of the AVP system.
Journal ArticleDOI
Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis
TL;DR: The physiological role of the serotonin transporter on serotonin neuronal membranes apparently is to inactivate serotonin that has been released into the synaptic cleft, and serotonin neurons decrease their firing and release of serotonin to limit the magnitude of the increase in extracellular serotonin concentration.
Journal ArticleDOI
Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum
Kenneth W. Perry,Ray W. Fuller +1 more
TL;DR: The increased extracellular concentration of serotonin no doubt resulted from inhibition of the serotonin uptake carrier by fluoxetine, and the lack of change in dopamine is evidence for the specificity of action of this uptake inhibitor.
Journal ArticleDOI
Dopamine deficiency in the weaver mutant mouse
Michael J. Schmidt,Barry D. Sawyer,Kenneth W. Perry,Ray W. Fuller,M. M. Foreman,Bernardino Ghetti +5 more
TL;DR: It is illustrated that weaver mice have specific deficiencies in the dopamine system and might provide a way of examining the biochemical and behavioral effects of long term dopamine deficiency and a way to examine drugs to treat dopamine-deficient states in vivo.
Journal ArticleDOI
Effect of an uptake inhibitor on serotonin metabolism in rat brain: Studies with 3-(p-trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine (Lilly 110140)
TL;DR: Lilly 110140 had no effect on brain levels of tryptophan, serotonin, dopamine, or norepinephrine, but it decreased 5-hydroxyindoleacetic acid (5HIAA) levels, and reduced turnover was indicated by a decreased rate of fall in brain serotonin levels after p-chlorophenylalamine was given to inhibit serotonin synthesis.